1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow PF-06730512: new trials by email Literature Review of PF-06730512 trials Research Report on PF-06730512
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) PF-06730512 - Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Terminated | Pfizer | 47 | 2018-10-15 | 2024-04-18 |
| Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512 PF-06730512, Placebo - Healthy | Phase 1 | Completed | Pfizer | 79 | 2017-05-10 | 2018-05-22 |
Glomerulosclerosis, Focal Segmental (1) · Proteinuria (1)
Pfizer (2)
Belgium (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · Poland (1) · Slovakia (1) · Spain (1) · United Kingdom (1) · United States (1)
2016 (1), 2019 (1)